Cover Image
市場調查報告書

代謝性疾病用醫藥品的全球市場:抗糖尿病藥物·抗甲狀腺藥·其他醫藥品 (副甲狀腺機能亢進症·下垂體功能降低症·腎上腺功能降低症)

Metabolic Disorders Drugs Global Market Report 2018

出版商 The Business Research Company 商品編碼 531331
出版日期 內容資訊 英文 125 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
代謝性疾病用醫藥品的全球市場:抗糖尿病藥物·抗甲狀腺藥·其他醫藥品 (副甲狀腺機能亢進症·下垂體功能降低症·腎上腺功能降低症) Metabolic Disorders Drugs Global Market Report 2018
出版日期: 2018年02月01日 內容資訊: 英文 125 Pages
簡介

本報告提供全球代謝性疾病用醫藥品的市場調查,提供市場定義和概要,市場的各種影響因素分析,各藥物部門·各地各國趨勢與市場規模的變化與預測,並彙整與宏觀經濟因素·醫療保健市場全體·各種產業指標的比較,競爭環境,企業簡介等資料。

第1章 市場特徵

第2章 市場規模·成長率

  • 市場成長:迄今的過程
    • 成長推進因素
    • 阻礙成長要素
  • 市場成長:預測
    • 成長推進因素
    • 阻礙成長要素

第3章 大環境分析

第4章 客戶資訊

第5章 代謝性疾病用醫藥品市場分析:各種類

  • 全球市場的實際成果:各種類
    • 抗糖尿病藥物
    • 抗甲狀腺藥
    • 其他
      • 副甲狀腺機能亢進症
      • 下垂體功能降低症
      • 腎上腺功能降低症
  • 全球市場的變化與預測:各種類
  • 市場趨勢·策略

第6章 代謝性疾病用醫藥品市場分析:各地各國分析

  • 全球市場的實際成果:各地區
  • 全球市場的變化與預測:各地區
  • 市場實際成果:各國
  • 市場變化與預測:各國
  • 全球醫藥品市場實際成果:部門·各地區
  • 全球醫藥品市場實際成果:部門·各國

第7章 宏觀經濟因素與市場比較

  • 市場規模的佔 GDP的百分比
  • 平均每個人的平均支出額

第8章 宏觀經濟因素與市場比較:各國

  • 市場規模的佔 GDP的百分比:各國
  • 平均每個人的平均支出額:各國

第9章 產業指標與市場比較

  • 全球藥劑師數:各國
  • 市場收益 vs 藥劑師數:各國
  • 全球醫藥品公司數:各國
  • 市場收益 vs 醫藥品公司數:各國
  • 全球對R&D/產品開發的平均支出額:各國
  • 市場收益 vs 對R&D/產品開發的平均支出額:各國
  • 全球非專利&品牌銷售額的比例:各國
  • 市場收益 vs 非專利&品牌銷售額的比例:各國
  • 高血壓的患病人數:各國
  • 全球一般開業醫生數:各國
  • 市場收益 vs 一般開業醫生數:各國

第10章 亞太地區市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類
  • 各國分析
  • 中國
  • 印度
  • 日本
  • 澳洲

第11章 西歐市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類
  • 各國分析
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙

第12章 東歐市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類
  • 各國分析
  • 俄羅斯

第13章 北美市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類
  • 各國分析
  • 美國

第14章 南美市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類
  • 各國分析
  • 巴西

第15章 中東市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類

第16章 非洲市場

  • 市場概要
  • 市場過去的轉變
  • 市場預測
  • 市場實際成果:各種類

第17章 競爭環境

  • 企業簡介
  • Novo Nordisk
  • Sanofi
  • Merck & Co.
  • Eli Lilly
  • Astrazeneca PLC

第18章 主要M&A:代謝性疾病用醫藥品市場

第19章 市場背景:醫藥品市場

第20章 醫藥品產業的Financial Margins

第21章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Metabolic Disorders Drugs Market Global Report 2018 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs market.

Where is the largest and fastest growing market for the metabolic disorders drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metabolic disorders drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider Healthcare market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
  • The metabolic disorders drugs market section of the report gives context. It compares the metabolic disorders drugs market with other segments of the Healthcare market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Metabolic Disorders Drugs Indicators Comparison.

Scope:

Markets Covered: Anti-diabetics drugs; Anti-thyroid drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

Companies Mentioned: Sanofi S.A,Novo Nordisk A/S,AstraZeneca Plc,Johnson & Johnson,Merck & Co

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Metabolic Disorders Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Reasons to Purchase:

  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Gain a global perspective on the development of the market.
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Table of Contents

1. Metabolic Disorders Drugs Market Characteristics

2. Metabolic Disorders Drugs Market Size And Growth

  • 2.1. Historic Market Growth, Value ($ Billion) and Volume (Million Units)
    • 2.1.1. Drivers Of The Market
    • 2.1.2. Restraints On The Market
  • 2.2. Forecast Market Growth, Value ($ Billion)
    • 2.2.1. Drivers Of The Market
    • 2.2.2. Restraints On The Market

3. Metabolic Disorders Drugs Trends And Strategies

4. Pestle Analysis

  • 4.1. Political
  • 4.2. Economic
  • 4.3. Social
  • 4.4. Technological
  • 4.5. Legal
  • 4.6. Environmental

5. Metabolic Disorders Drugs Market Customer Information

6. Metabolic Disorders Drugs Market Regional And Country Analysis

  • 6.1. Global Metabolic Disorders Drugs Market, 2017, By Region, Value ($ Billion) and Volume (Million Units)
  • 6.2. Global Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, By Region
  • 6.3. Global Metabolic Disorders Drugs Market, Growth And Market Share Comparison, By Region
  • 6.4. Global Metabolic Disorders Drugs Market, 2017, By Country, Value ($ Billion) and Volume (Million Units)
  • 6.5. Global Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, By Country
  • 6.6. Global Metabolic Disorders Drugs Market, Growth And Market Share Comparison, By Country

7. Metabolic Disorders Drugs Market Segmentation

  • 7.1. Global Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

  • 7.2. Global Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)

8. Metabolic Disorders Drugs Market Segments

  • 8.1.Anti-diabetics drugs

a) Market Characteristics

b) Market Trends & Strategies

c) Global Anti-diabetics drugs Market, 2017, By Segment, Value ($ Billion)

  • 8.2.Anti-thyroid drugs

a) Market Characteristics

b) Market Trends & Strategies

c) Global Anti-thyroid drugs Market, 2017, By Segment, Value ($ Billion)

  • 8.3.Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

a) Market Characteristics

b) Market Trends & Strategies

c) Global Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) Market, 2017, By Segment, Value ($ Billion)

9. Global Metabolic Disorders Drugs Market Comparison With Macro Economic Factors

  • 9.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, Global
  • 9.2. Per Capita Average Metabolic Disorders Drugs Expenditure, Global

10. Metabolic Disorders Drugs Market Comparison With Macro Economic Factors Across Countries

  • 10.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, By Country
  • 10.2. Per Capita Average Metabolic Disorders Drugs Expenditure, By Country

11. Metabolic Disorders Drugs Market Comparison With Industry Metrics

  • 11.1. Global Number Of Pharmacists, 2017, By Country
  • 11.2. Global Metabolic Disorders Market Revenue Versus Number Of Pharmacists, 2017, By Country
  • 11.3. Global Number Of Pharma Enterprises, 2017, By Country
  • 11.4. Global Metabolic Disorders Market Revenue Versus Number Of Pharma Enterprises, 2017, By Country
  • 11.5. Global Average Spending On R&D/Product Development, 2017, By Country
  • 11.6. Global Metabolic Disorders Market Revenue Versus Average Spending On R&D/Product Development, 2017, By Country
  • 11.7. Global Generic & Branded Sales Proportion By Country (Value), 2017, By Country
  • 11.8. Global Metabolic Disorders Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2017, By Country
  • 11.9. Prevalent Cases Of Hypertension, 2014, By Country
  • 11.10. Prevalent Cases Of Diabetes, 2015, By Country
  • 11.11. Global Number Of General Practitioners 2017, By Country
  • 11.12. Global Metabolic Disorders Market Revenue Versus Number Of General Practitioners, 2017, By Country

12. Asia-Pacific Metabolic Disorders Drugs Market

    • 12.1.1. Asia-Pacific Metabolic Disorders Drugs Market Overview
    • 12.1.2. Asia-Pacific Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 12.1.3. Asia-Pacific Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 12.1.4. Asia-Pacific Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 12.1.5. Asia-Pacific Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 12.2. Asia-Pacific Metabolic Disorders Drugs Market: Country Analysis
  • 12.3. China Metabolic Disorders Drugs Market
    • 12.3.1. China Metabolic Disorders Drugs Market Overview
    • 12.3.2. China Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 12.3.3. China Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 12.3.4. China Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 12.3.5. China Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 12.4. India Metabolic Disorders Drugs Market
    • 12.4.1. India Metabolic Disorders Drugs Market Overview
    • 12.4.2. India Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 12.4.3. India Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 12.4.4. India Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 12.4.5. India Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 12.5. Japan Metabolic Disorders Drugs Market
    • 12.5.1. Japan Metabolic Disorders Drugs Market Overview
    • 12.5.2. Japan Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 12.5.3. Japan Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 12.5.4. Japan Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 12.5.5. Japan Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 12.6. Australia Metabolic Disorders Drugs Market
    • 12.6.1. Australia Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 12.6.2. Australia Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 12.6.3. Australia Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 12.6.4. Australia Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)

13. Western Europe Metabolic Disorders Drugs Market

    • 13.1.1. Western Europe Metabolic Disorders Drugs Market Overview
    • 13.1.2. Western Europe Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 13.1.3. Western Europe Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 13.1.4. Western Europe Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 13.1.5. Western Europe Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 13.2. Western Europe Metabolic Disorders Drugs Market: Country Analysis
  • 13.3. UK Metabolic Disorders Drugs Market
    • 13.3.1. UK Metabolic Disorders Drugs Market Overview
    • 13.3.2. UK Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 13.3.3. UK Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 13.3.4. UK Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 13.3.5. UK Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 13.4. Germany Metabolic Disorders Drugs Market
    • 13.4.1. Germany Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 13.4.2. Germany Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 13.4.3. Germany Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 13.4.4. Germany Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 13.5 France Metabolic Disorders Drugs Market
    • 13.5.1 France Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 13.5.2 France Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 13.5.3. France Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 13.5.4. France Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 13.6. Italy Metabolic Disorders Drugs Market
    • 13.6.1. Italy Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 13.6.2. Italy Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 13.6.3. Italy Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 13.6.4. Italy Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 13.7. Spain Metabolic Disorders Drugs Market
    • 13.7.1. Spain Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 13.7.2. Spain Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 13.7.3. Spain Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 13.7.4. Spain Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)

14. Eastern Europe Metabolic Disorders Drugs Market

    • 14.1.1. Eastern Europe Metabolic Disorders Drugs Market Overview
    • 14.1.2. Eastern Europe Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 14.1.3. Eastern Europe Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 14.1.4. Eastern Europe Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 14.1.5. Eastern Europe Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 14.2. Eastern Europe Metabolic Disorders Drugs Market: Country Analysis
  • 14.3. Russia Metabolic Disorders Drugs Market
    • 14.3.1. Russia Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 14.3.2. Russia Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 14.3.3. Russia Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 14.3.4. Russia Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)

15. North America Metabolic Disorders Drugs Market

    • 15.1.1. North America Metabolic Disorders Drugs Market Overview
    • 15.1.2. North America Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 15.1.3. North America Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 15.1.4. North America Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 15.1.5. North America Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 15.2. North America Metabolic Disorders Drugs Market: Country Analysis
  • 15.3. USA Metabolic Disorders Drugs Market
    • 15.3.1. USA Metabolic Disorders Drugs Market Overview
    • 15.3.2. USA Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 15.3.3. USA Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 15.3.4. USA Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 15.3.5. USA Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)

16. South America Metabolic Disorders Drugs Market

    • 16.1.1. South America Metabolic Disorders Drugs Market Overview
    • 16.1.2. South America Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 16.1.3. South America Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 16.1.4. South America Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 16.1.5. South America Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)
  • 16.2. South America Metabolic Disorders Drugs Market: Country Analysis
  • 16.3. Brazil Metabolic Disorders Drugs Market
    • 16.3.1. Brazil Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 16.3.2. Brazil Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 16.3.3. Brazil Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 16.3.4. Brazil Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)

17. Middle East Metabolic Disorders Drugs Market

    • 17.1.1. Middle East Metabolic Disorders Drugs Market Overview
    • 17.1.2. Middle East Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 17.1.3. Middle East Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 17.1.4. Middle East Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 17.1.5. Middle East Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)

18. Africa Metabolic Disorders Drugs Market

    • 18.1.1. Africa Metabolic Disorders Drugs Market Overview
    • 18.1.2. Africa Metabolic Disorders Drugs Historic Market, 2013 - 2017, Value ($ Billion) and Volume (Million Units)
    • 18.1.3. Africa Metabolic Disorders Drugs Forecast Market, 2017 - 2021, Value ($ Billion)
    • 18.1.4. Africa Metabolic Disorders Drugs Market, 2017, Segmentation By Type, Value ($ Billion)

Anti-diabetics drugs

Anti-thyroid drugs

Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

    • 18.1.5. Africa Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, Segmentation By Type, Value ($ Billion)

19. Metabolic Disorders Drugs Market Competitive Landscape

  • 19.1. Company Profiles
  • 19.2. Sanofi S.A
    • 19.2.1. Overview
    • 19.2.2. Products And Services
    • 19.2.3. Strategy
    • 19.2.4. Financial Performance
  • 19.3. Novo Nordisk A/S
    • 19.3.1. Overview
    • 19.3.2. Products And Services
    • 19.3.3. Strategy
    • 19.3.4. Financial Performance
  • 19.4. AstraZeneca Plc
    • 19.4.1. Overview
    • 19.4.2. Products And Services
    • 19.4.3. Strategy
    • 19.4.4. Financial Performance
  • 19.5. Johnson & Johnson
    • 19.5.1. Overview
    • 19.5.2. Products And Services
    • 19.5.3. Strategy
    • 19.5.4. Financial Performance
  • 19.6. Merck & Co
    • 19.6.1. Overview
    • 19.6.2. Products And Services
    • 19.6.3. Strategy
    • 19.6.4. Financial Performance

20. Key Mergers And Acquisitions In The Metabolic Disorders Drugs Market

21. Market Background: Metabolic Disorders Drugs Market

    • 21.1.1. Metabolic Disorders Drugs Market Characteristics
    • 21.1.2. Metabolic Disorders Drugs Market Historic Growth, Value ($ Billion)
      • 21.1.2.1. Drivers Of The Market
      • 21.1.2.2. Restraints Of The Market
    • 21.1.3. Metabolic Disorders Drugs Market Forecast Growth, Value ($ Billion)
      • 21.1.3.1. Drivers Of The Market
      • 21.1.3.2. Restraints Of The Market
    • 21.1.4. Metabolic Disorders Drugs Trends And Strategies
  • 21.2. Metabolic Disorders Drugs Market Regional And Country Analysis
    • 21.2.1. Global Metabolic Disorders Drugs Market, 2017, By Region, Value ($ Billion) and Volume (Million Units)
    • 21.2.2. Global Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, By Region
    • 21.2.3. Metabolic Disorders Drugs Market, 2017, By Country, Value ($ Billion) and Volume (Million Units)
    • 21.2.4. Metabolic Disorders Drugs Market, 2013 - 2021, Historic And Forecast, By Country
    • 21.2.5. Metabolic Disorders Drugs Market, Growth And Market Share Comparison, By Segment
    • 21.2.6. Metabolic Disorders Drugs Market, Growth And Market Share Comparison, By Country And Segment
  • 21.3. Global Metabolic Disorders Drugs Market Comparison With Macro Economic Factors
    • 21.3.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, Global
    • 21.3.2. Per Capita Average Metabolic Disorders Drugs Expenditure, Global
  • 21.4. Metabolic Disorders Drugs Market Comparison With Macro Economic Factors Across Countries
    • 21.4.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, By Country
    • 21.4.2. Per Capita Average Metabolic Disorders Drugs Expenditure, By Country
  • 21.5. Key Mergers And Acquisitions In The Metabolic Disorders Drugs Market

22. Appendix

  • 22.1. NAICS Definitions Of Industry Covered In This Report
  • 22.2. Abbreviations
  • 22.3. Currencies
  • 22.4. Research Inquiries
  • 22.5. The Business Research Company
  • 22.6. Copyright And Disclaimer
Back to Top